多肿瘤标志物蛋白芯片检测系统在消化系统疾病的应用评价

目的评价多肿瘤标志物联合检测在消化系统疾病的应用。方法使用HD-2OO1A多肿瘤标志物蛋白芯片检测系统（C12）联合检测2007年2月至2010年2月消化科住院患者393例血清肿瘤标志物。结果恶性肿瘤组和良性疾病组C12单个肿瘤标志物阳性率分别为67.44%和30.68%,肿瘤组显著高于良性疾病组（P〈0.01）。肿瘤组敏感度较高的前四项组合为：肝癌组CA19-9、AFP、CA125、CEA;结直肠癌组、胃癌组、胰腺癌和胆管癌/胆囊癌、小肠癌CEA、CA19-9、CA242和CA125;食管癌CEA、CA125、CA153、FER。而肿瘤标志物在良性疾病的表达：急性胰腺炎组CA19-9（53.66%）;胃十二指肠溃疡组CEA（40.91%）;胆囊炎组CA19-9（57.89%）;肝硬化组CA125（87.5%）。结论运用蛋白芯片技术检测多肿瘤标志物可以明显提高恶性肿瘤诊断的敏感度,可作为肿瘤诊断及高危人群早期筛查等辅助检查。同时,多肿瘤标志物在消化道良性疾病也有表达,提示是否可作为疾病发展进程的监测指标有待进一步研究。

Evaluation of clinical application of detective system using multi-tumor markers protein biochip in digestive disease

Objective To evaluate the application of detective system using multi-tumor markers protein biochip in digestive disease.Methods The serum levels of 12 tumor markers were detected in 393 inpatients of gastroenterology department from February 2007 to February 2010.Results The positive rates 67.44% and 30.68% were detected by C12 system in digestive cancer group and benign disease group,respectively.The digestive cancer group had significantly higher than that of benign digestive disease（P0.01）.The fourth combination of tumor marker in cancer group were：liver cancer CA19-9、AFP/CA125、CEA;colorectal carcinoma,gastric cancer,pancreatic cancer,cholangiocarcinoma/gallbladder cancer,intestinal cancer CEA、CA19-9、CA242、CA125;esophageal cancer CEA/CA125/HGH/CA153/FER,respectively.Tumor marker also expressed in benign disease：pancreatitis CA19-9（53.66%）,gastroduodenal ulcer CEA（40.91%）,cholecystitis CA19-9（57.89%）and cirrhosis CA125（87.5%）,respectively.Conclusion Combined measurement of multi-tumor markers using protein biochip technique can significantly increase the diagnostic sensitivity of digestive malignant tumor,and also be used as an earlier tumor-screening tool for high risk people.Meanwhile,multi-tumor markers express in digestive benign disease.It suggests that tumor marker maybe monitor for progress of disease.This needs to be further study.